8th Translational Research Conference
Multiple Myeloma
March 26-28, 2026 – Stockholm, Sweden
Chairpersons : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch

Thursday, March 26, 2026

08:35–08:45 Welcome by Conference Chairpersons

08:45-09:15 **Keynote Lecture**
Chair: Martin Kaiser (London)

08:45-09:15	How I brought translational medicine from bench to bedside	Kenneth C. Anderson (Boston)

SESSION I – MGUS
Chair: Martin Kaiser (London)

09:15-09:20	Introduction	Martin Kaiser (London)
09:20-09:35	Screening a healthy population for precursors?	Sigrun Thorsteinsdottir (Copenhagen)
09:35-09:50	Flowcytometric characterization of MGUS and SMM	Alberto Orfao (Salamanca)
09:50-10:05	Immune evolution in plasma cell dyscrasias	Madhav Dhodapkar (Atlanta)
10:05-10:10	Brief oral communication *Lipidomic and Metabolomic Characterisation of Progression from Healthy to MGUS to SMM in the i.StopMM Cohort*	Kyeong-Seog Kim (Liverpool)
10:10-10:12	*Discussion*	
10:12-10:40	*Panel discussion*	

10:40-11:10 Coffee Break

SESSION II – Smouldering myeloma
Chair: Ola Landgren (Miami)

11:10-11:15	Introduction	Ola Landgren (Miami)
11:15-11:30	How to identify high-risk smouldering multiple myeloma?	Ajay Nooka (Atlanta)
11:30-12:00	**DEBATE**: To treat or not to treat smouldering multiple myeloma?	

Audience votes

11:30-11:45	YES	Meletios Dimopoulos (Athens)
11:45-12:00	NO	Martin Kaiser (London)

Audience votes

12:00-12:05	Brief oral communication *Levels of antibody against thymus-dependent but not thymus independent bacterial antigens are compromised in myeloma precursor disease*	Sian Faustini (Birmingham)
12:05-12:07	*Discussion*	
12:07-12:35	*Panel discussion*	

12:35-13:50 Lunch

SESSION III – Characterising multiple myeloma
Chair: Alberto Orfao (Salamanca)

13:50-13:55	Introduction	Alberto Orfao (Salamanca)
13:55-14:10	Molecular drivers of multiple myeloma	Tom Cupedo (Rotterdam)
14:10-14:25	CAR-T cell transcriptional programs that define efficacy and toxicity	Karlo Perica (New York)
14:25-14:40	Imaging in plasma cell dyscrasias: How, when and how often?	Jens Hillengass (Buffalo)
14:40-15:10	**DEBATE**: MRI or PET CT: who is the winner?	

Audience votes

14:40-14:55	Whole body MRI in multiple myeloma: precision medicine demands precision diagnostics.	Christina Messiou (Sutton)
14:55-15:10	PET CT	Françoise Bodere (Nantes)

Audience votes

15:10-15:15	Brief oral communication *Bispecific anti-CCR4/BCMA CAR-T cells concomitantly target the tumor and the immunosuppressive microenvironment in multiple myeloma*	Juan Pablo Ortiz-Aguirre (Berlin)
15:15-15:17	*Discussion*	
15:17-15:45	*Panel discussion*	

15:45-16:15 Coffee break

SESSION IV – Newly diagnosed fit multiple myeloma patients
Chair: Elias Mai (Heidelberg)

16:15-16:20	Introduction	Elias Mai (Heidelberg)

16:20-16:35	Newly diagnosed multiple myeloma patients	Roberto Mina (Atlanta)
16:35-17:05	**DEBATE:** Transplant vs CAR-T cells	
Audience votes		
16:35-16:50	Autologous transplant vs. CAR-T in young, newly diagnosed myeloma — why transplant still matters	Mohammad Mohty (Paris)
16:50-17:05	CAR-T Cells	Robert Orlowski (Houston)
Audience votes		
17:05-17:20	Double vs single standard maintenance	Elias Mai (Heidelberg)
17:20-17:25	Brief oral communication *Venous and Arterial Thromboembolism in Newly Diagnosed Multiple Myeloma: Incidence, Timing and Risk factors from the UK NCRI Myeloma-XI Trial*	Sina A Beer (London)
17:25-17:27	*Discussion*	
17:27-18:05	*Panel discussion*	
18:10-20:00	**Mentored Poster Walk and Welcome Get Together** *Poster Walk leaders : Meral Beksac (Ankara), Klaus Podar (Krems)*	

Friday, March 27th, 2026

SESSION V – Role of frailty for treatment decisions
Chair: Charlotte Pawlyn (London)

09:30-09:35	Introduction	Charlotte Pawlyn (London)
09:35-09:50	Who's the frail patient?	Charlotte Pawlyn (London)
09:50-10:05	Is there a limit for induction therapy in multiple myeloma?	Klaus Podar (Krems)
10:05-10:20	ADCs or Bites or CAR-T in frail patients?	Johan Lund (Stockholm)
10:20-10:35	MRD driven or QoL driven maintenance in older patients?	Ola Landgren (Miami)
10:35-10:40	Brief oral communication *Locking in BCMA: SHEDLOCK CAR-T Cells Prevent Gamma-Secretase - Mediated Shedding of BCMA and enhance Efficacy Against Multiple Myeloma*	Sheetal Sharma (New Delhi)
10:40-10:42	*Discussion*	
10:42-11:10	*Panel discussion*	
11:25-12:25	**2 Simultaneous Meet the Expert Sessions** 1. Red flags of AL Amyloidosis 2. MRD as endpoint in myeloma	 Morie Gertz (Rochester) Luciano Costa (Birmingham, AL)
12:25-13:35	***Lunch***	

SESSION VI – Personalising treatment in multiple myeloma
Chair: Marc Raab (Heidelberg)

13:35-13:40	Introduction	Marc Raab (Heidelberg)
13:40-13:55	Treatment decision making in high-risk multiple myeloma	Martin Kaiser (London)
13:55-14:10	Management of side effects of CAR-Ts and Bispecifics	Nico Gagelmann (Boston)
14:10-14:25	MRD-directive therapies	Luciano Costa (Birmingham, AL)
14:25-14:40	Precision medicine in multiple myeloma- Future or Reality	Marc Raab (Heidelberg)
14:40-15:15	*Panel discussion*	
15:15-15:45	***Coffee break***	

SESSION VII – Relapsed multiple myeloma
Chair: Nico Gagelmann (Boston)

15:45-15:50	Introduction	Nico Gagelmann (Boston)
15:50-16:05	When to start treatment to prevent organ damage in relapsed multiple myeloma	Meral Beksac (Ankara)
16:05-16:20	BCMA-ADCs combination treatments for relapsed MM	Fredrik Schjesvold (Oslo)
16:20-16:35	When to use GPRC5D targeted treatment	Sham Mailankody (New York)
16:35-16:50	Sequencing of BCMA treatment : ADCs, BiTEs or CAR-T ?	Samer Al Hadidi (Dallas)
16:50-16:55	Brief Oral Communication *Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in Relapsed/Refractory Multiple Myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 Study*	Luciano Costa (Birmingham)
16:55-16:57	*Discussion*	
16:57-17:25	*Panel discussion*	

Saturday, March 28th 2026

SESSION VIII – Novel technologies for tailored treatment
Chair: Marc Raab (Heidelberg)

08:30-08:35	Introduction	Marc Raab (Heidelberg)
08:35-08:50.	Using immune profiling to direct cellular therapies	Leo Rasche (Würzburg)
08:50-09:05.	Personalized tumour tracking by mass spectrumetry	Elias Mai (Heidelberg)
09:05-09:20.	Developing an open-access CAR-T, from discovery to licensing	Krina Patel (Houston)

09:20-09:35	Role of NK cells in myeloma	Evren Alici (Stockholm)
09:35-09:50	Trispecifics T-cell and bispecific NK-Cell engagers in myeloma treatment	Marc Raab (Heidelberg)
09:50-09:55	Brief Oral Communication *CD38 expression on T-cells in patients with B-cell malignancies is a potential biomarker for CAR-T manufacturing failures*	Jeyan Jayarajan (Berlin)
09:55-09:57	*Discussion*	
09:57-10:25	*Panel discussion*	
10:25-10:55	***Coffee break***	

SESSION IX – Amyloidosis and Waldenstrom's Disease
Chair: Martin Kaiser (London)

10:55-11:00	Introduction	Martin Kaiser (London)
11:00-11:15	Cytogenetics and risk assessment in AL Amyloidosis	Stefan Schönland (Heidelberg)
11:15-11:30	Targeted treatment in relapsed AL amyloidosis	Rajshekhar Chakraborty (New York)
11:30-11:45	Immunotherapy as Anti-Amyloid Strategies	Rajshekhar Chakraborty (New York)
11:45-12:00	Latest approaches to treat Waldenstrom's disease	Morie Gertz (Rochester)
12:00-12:05	Brief Oral Communication *Genome-wide CRISPR Cas9 screens identify alterations in apoptosis, proteasome activity, and autophagy pathways to confer carfilzomib resistance in multiple myeloma*	Maja Zimmer Jakobsen (Aalborg)
12:05-12:07	*Discussion*	
12:07-12:35	*Panel discussion*	
12:35-12:45	***Closing Remarks***	

MEETING CLOSURE